{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:18:00Z","timestamp":1791505080130,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K022733\/1"],"award-info":[{"award-number":["MR\/K022733\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome","doi-asserted-by":"publisher","award":["WT 203148\/Z\/16\/Z"],"award-info":[{"award-number":["WT 203148\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"EPSRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004941","name":"Guy's and St Thomas' NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009360","name":"King\u2019s College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009360","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010872","name":"King's College Hospital NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010872","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Centre of Excellence in Medical Engineering"},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT 088641\/Z\/09\/Z"],"award-info":[{"award-number":["WT 088641\/Z\/09\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"EPSRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.nucmedbio.2018.11.002","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T07:41:51Z","timestamp":1541749311000},"page":"14-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Development of [18F]FAMTO: A novel fluorine-18 labelled positron emission tomography (PET) radiotracer for imaging CYP11B1 and CYP11B2 enzymes in adrenal glands"],"prefix":"10.1016","volume":"68-69","author":[{"given":"Salvatore","family":"Bongarzone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Basagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Sementa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1312-688X","authenticated-orcid":false,"given":"Nisha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Gakpetor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Faugeras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6547-9476","authenticated-orcid":false,"given":"Jayanta","family":"Bordoloi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8389-9012","authenticated-orcid":false,"given":"Antony D.","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11906-003-0012-2","article-title":"Aldosterone: a risk factor for vascular disease","volume":"5","author":"Fritsch Neves","year":"2003","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0010","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone: effects on the kidney and cardiovascular system","volume":"6","author":"Briet","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0020","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MED.0000000000000148","article-title":"Nuclear imaging in the diagnosis of primary aldosteronism","volume":"22","author":"Powlson","year":"2015","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0025","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline","volume":"93","author":"Funder","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1291\/hypres.27.193","article-title":"Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan","volume":"27","author":"Omura","year":"2004","journal-title":"Hypertens Res"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0035","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0040","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1530\/eje.0.1470795","article-title":"Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas","volume":"147","author":"Fallo","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0045","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nrendo.2011.76","article-title":"A comprehensive review of the clinical aspects of primary aldosteronism","volume":"7","author":"Rossi","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0050","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1161\/HYPERTENSIONAHA.115.06305","article-title":"Clinical management and outcomes of adrenal hemorrhage following adrenal vein sampling in primary aldosteronism","volume":"67","author":"Monticone","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0055","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/HYPERTENSIONAHA.111.175083","article-title":"Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms)","volume":"58","author":"Mulatero","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0060","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0065","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejrad.2007.10.024","article-title":"Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas","volume":"69","author":"Hennings","year":"2009","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18040848","article-title":"Subtype diagnosis of primary aldosteronism: is adrenal vein sampling always necessary?","volume":"18","author":"Buffolo","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0075","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.surg.2004.06.051","article-title":"Role for adrenal venous sampling in primary aldosteronism","volume":"136","author":"Young","year":"2004","journal-title":"Surgery"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0080","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1161\/HYPERTENSIONAHA.110.168484","article-title":"Adrenal venous sampling: evaluation of the German Conn's registry","volume":"57","author":"Vonend","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0085","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMc070612","article-title":"The incidentally discovered adrenal mass","volume":"356","author":"Gavras","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0090","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMcp065470","article-title":"Clinical practice. The incidentally discovered adrenal mass","volume":"356","author":"Young","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0095","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.tem.2005.02.007","article-title":"Diagnosis of primary aldosteronism: from screening to subtype differentiation","volume":"16","author":"Mulatero","year":"2005","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0100","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1590\/0100-3984.2013.1762","article-title":"Imaging of the adrenal gland lesions","volume":"47","author":"Herr","year":"2014","journal-title":"Radiol Bras"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0105","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1210\/jc.2011-1537","article-title":"Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas","volume":"97","author":"Burton","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0110","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1016\/0006-2952(84)90052-2","article-title":"Effects of etomidate on steroid biosynthesis in subcellular fractions of bovine adrenals","volume":"33","author":"Vanden Bossche","year":"1984","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0115","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1021\/jm401430e","article-title":"Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases","volume":"57","author":"Hu","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0120","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10822-007-9128-9","article-title":"Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics","volume":"21","author":"Roumen","year":"2007","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0125","first-page":"982","article-title":"In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors","volume":"39","author":"Bergstrom","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0130","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1210\/jc.2015-3431","article-title":"A novel CYP11B2-specific imaging agent for detection of unilateral subtypes of primary aldosteronism","volume":"101","author":"Abe","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0135","first-page":"275","article-title":"PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate","volume":"41","author":"Bergstrom","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0140","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00259-002-1025-9","article-title":"11C-metomidate PET imaging of adrenocortical cancer","volume":"30","author":"Khan","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0145","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1210\/jc.2005-2273","article-title":"[11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings","volume":"91","author":"Hennings","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0150","first-page":"972","article-title":"Imaging of adrenal incidentalomas with PET using 11C-metomidate and (18)F-FDG","volume":"45","author":"Minn","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0155","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1095-0397(99)00099-0","article-title":"PET with [11C]-metomidate for the visualization of adrenocortical tumors and discrimination from other lesions","volume":"2","author":"Bergstrom","year":"1999","journal-title":"Clin Positron Imaging"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0160","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/jlcr.1517","article-title":"Synthesis of 11C-labelled metomidate analogues as adrenocortical imaging agents","volume":"51","author":"Karimi","year":"2008","journal-title":"J Label Compd Radiopharm"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0165","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/jlcr.680","article-title":"Synthesis of [18F]FETO, a novel potential 11-\u03b2 hydroxylase inhibitor","volume":"46","author":"Wadsak","year":"2003","journal-title":"J Label Compd Radiopharm"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0170","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1021\/jm800012w","article-title":"New selective inhibitors of steroid 11beta-hydroxylation in the adrenal cortex. Synthesis and structure-activity relationship of potent etomidate analogues","volume":"51","author":"Zolle","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0175","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jlcr.1742","article-title":"Automated synthesis of F-18-labelled analogs of metomidate, vorozole and harmine using commercial platform","volume":"53","author":"Rahman","year":"2010","journal-title":"J Label Compd Radiopharm"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0180","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.nucmedbio.2009.01.014","article-title":"18F-labelled metomidate analogues as adrenocortical imaging agents","volume":"36","author":"Erlandsson","year":"2009","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0185","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s00259-006-0123-5","article-title":"[18F]FETO: metabolic considerations","volume":"33","author":"Ettlinger","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0190","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1524\/ract.92.4.297.35598","article-title":"[123\/131I]Iodometomidate as a radioligand for functional diagnosis of adrenal disease: synthesis, structural requirements and biodistribution","volume":"92","author":"Schirbel","year":"2009","journal-title":"Radiochim Acta"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0195","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1021\/mp3006227","article-title":"[(3)H]metyrapol and 4-[131I]iodometomidate label overlapping, but not identical, binding sites on rat adrenal membranes","volume":"10","author":"Berger","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0200","doi-asserted-by":"crossref","first-page":"v","DOI":"10.1016\/j.nucmedbio.2017.09.004","article-title":"Consensus nomenclature rules for radiopharmaceutical chemistry - setting the record straight","volume":"55","author":"Coenen","year":"2017","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0205","doi-asserted-by":"crossref","DOI":"10.1038\/srep09941","article-title":"Sulfonium salts as leaving groups for aromatic labelling of drug-like small molecules with fluorine-18","volume":"5","author":"Sander","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0210","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1021\/acs.orglett.5b02875","article-title":"Synthesis of [18F]arenes via the copper-mediated [18F]fluorination of boronic acids","volume":"17","author":"Mossine","year":"2015","journal-title":"Org Lett"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0215","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.1002\/chem.201405586","article-title":"Copper-mediated aromatic radiofluorination revisited: efficient production of PET tracers on a preparative scale","volume":"21","author":"Zlatopolskiy","year":"2015","journal-title":"Chem A Eur J"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0220","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/diagnostics6040042","article-title":"Targeted molecular imaging in adrenal disease-an emerging role for metomidate PET-CT","volume":"6","author":"Mendichovszky","year":"2016","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0225","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/ejoc.201101730","article-title":"18F-radiolabeling of aromatic compounds using triarylsulfonium salts","author":"Mu","year":"2012","journal-title":"Eur J Org Chem"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0230","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1530\/EJE-10-1085","article-title":"Gene expression profiles in aldosterone-producing adenomas and adjacent adrenal glands","volume":"164","author":"Wang","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0235","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000137268","article-title":"Etomidate and plasma esterase activity in man and experimental animals","volume":"18","author":"Calvo","year":"1979","journal-title":"Pharmacology"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0240","first-page":"72","article-title":"Intravenous pharmacokinetic profile in rats of etomidate, a short-acting hypnotic drug","volume":"220","author":"Lewi","year":"1976","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1016\/j.nucmedbio.2018.11.002_bb0245","first-page":"113","article-title":"Distribution, metabolism and excretion of etomidate, a short-acting hypnotic drug, in the rat. Comparative study of (R)-(+)-(\u2212)-etomidate","volume":"216","author":"Heykants","year":"1975","journal-title":"Arch Int Pharmacodyn Ther"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980511830235X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980511830235X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T06:21:55Z","timestamp":1720765315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096980511830235X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":49,"alternative-id":["S096980511830235X"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2018.11.002","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of [18F]FAMTO: A novel fluorine-18 labelled positron emission tomography (PET) radiotracer for imaging CYP11B1 and CYP11B2 enzymes in adrenal glands","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2018.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}